Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Boosted by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC lifted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 100.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 54,499 shares of the biopharmaceutical company's stock after buying an additional 27,331 shares during the quarter. Knights of Columbus Asset Advisors LLC owned approximately 0.06% of Intra-Cellular Therapies worth $3,903,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Intra-Cellular Therapies by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,539,725 shares of the biopharmaceutical company's stock worth $444,834,000 after purchasing an additional 43,689 shares during the period. BlackRock Inc. increased its holdings in Intra-Cellular Therapies by 13.1% during the 1st quarter. BlackRock Inc. now owns 6,470,417 shares of the biopharmaceutical company's stock worth $395,924,000 after purchasing an additional 748,651 shares during the period. Wellington Management Group LLP purchased a new stake in Intra-Cellular Therapies during the 1st quarter worth about $248,502,000. State Street Corp increased its holdings in Intra-Cellular Therapies by 3.9% during the 2nd quarter. State Street Corp now owns 2,105,705 shares of the biopharmaceutical company's stock worth $133,333,000 after purchasing an additional 79,477 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Intra-Cellular Therapies by 4.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,063,802 shares of the biopharmaceutical company's stock worth $107,503,000 after purchasing an additional 86,388 shares during the period. Hedge funds and other institutional investors own 92.33% of the company's stock.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 40,712 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $66.50, for a total transaction of $2,707,348.00. Following the completion of the sale, the chief executive officer now directly owns 1,050,309 shares of the company's stock, valued at approximately $69,845,548.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Intra-Cellular Therapies news, CEO Sharon Mates sold 40,712 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $66.50, for a total transaction of $2,707,348.00. Following the completion of the sale, the chief executive officer now directly owns 1,050,309 shares of the company's stock, valued at approximately $69,845,548.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Halstead sold 7,907 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $69.53, for a total value of $549,773.71. Following the sale, the executive vice president now directly owns 29,700 shares of the company's stock, valued at $2,065,041. The disclosure for this sale can be found here. In the last ninety days, insiders sold 168,487 shares of company stock valued at $11,364,950. 3.40% of the stock is owned by company insiders.

Intra-Cellular Therapies Trading Up 0.5 %

Shares of NASDAQ ITCI traded up $0.37 during trading hours on Friday, reaching $72.37. The stock had a trading volume of 2,189,254 shares, compared to its average volume of 1,188,995. The firm has a market cap of $7.01 billion, a price-to-earnings ratio of -49.57 and a beta of 1.02. Intra-Cellular Therapies, Inc. has a fifty-two week low of $45.50 and a fifty-two week high of $84.89. The firm has a 50-day moving average of $69.31 and a 200-day moving average of $64.19.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.14. The firm had revenue of $132.10 million during the quarter, compared to analysts' expectations of $135.97 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The business's revenue was up 50.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.45) EPS. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.67 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ITCI. TD Cowen upped their price target on Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a "buy" rating in a report on Wednesday. Bank of America upped their price objective on Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a "buy" rating in a research report on Wednesday. The Goldman Sachs Group upped their price objective on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a "neutral" rating in a research report on Wednesday. Canaccord Genuity Group lowered their price objective on Intra-Cellular Therapies from $101.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, February 23rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $86.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $86.17.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.